Existing in vitro culture technology does not permit the routine propagation of most human myeloid leukemias. Previous work has shown the usefulness of mice with severe combined immunodeficiency (SCID) for the growth of human lymphoblastic leukemia. We show here that human myeloid cell lines and bone marrow samples from patients with acute myeloid leukemia (AML) and blast crisis of chronic myeloid leukemia (CML) also grow in SClD mice. Human AML or CML cell lines (three of three lines tested) grew in the bone marrow and peripheral blood of the mice after intravenous (W) inoculation in a pattern closely resembling human AML. To define the best conditions for the growth of primary human myeloid leukemia cells, samples were transplanted into mice at several alternative sites. Using flow cytometry and Southern analysis, mice were analyzed at defined inter-TUDIES OF THE ex vivo biologic behavior of human S myeloid leukemias are generally limited to immortalized cell lines, short-term in vitro culture of primary explants, and assays on fresh clinical samples. Only rarely will human acute myeloid leukemia (AML) samples adapt to growth in tissue culture,' suggesting that these cell lines represent a subset of human myeloid leukemias or that a genetic alteration occurs during culture of the explant that permits immortalization. Conclusions based on analysis of these lines may not be representative of human myeloid leukemia. What is needed is a system that permits the routine growth of leukemia cells obtained directly from patients.
Long-term human bone marrow (BM) culture is an established technique for the growth of normal human myeloid cells in vitro over a period of several but extension of this technology to human myeloid leukemias has not been as successful. AML cells differentiate to monocytes and neutrophils and cultures generally die out over several weeks' or are overgrown by normal hematopoietic cells.637 In vitro models for human leukemia also fail to address critical issues such as cellular interactions between the leukemia clone and supporting tissue as well as invasiveness of human leukemias into nonhematopoietic tissues. A small animal model to reproducibly grow human myeloid leukemia samples is needed to examine these issues.
Previous attempts to establish an animal model for human myeloid leukemia have focused on the immunedeficient nude mouse. Although xenotransplantation of human solid tumor tissues from patients is widely used, human hematopoietic malignancies have proved difficult to propagate? Cell lines will grow reproducibly as a localized mass after subcutaneous implantation without spreading to the murine hematopoietic t i s s~e s .~"~ Recently, several groups have reported the successful transfer of normal or leukemic human lymphoid cells into severe combined immunodeficiency (SCID) In contrast to prior studies of human leukemia growth in nude mice, the human lymphoblasts grew in the BM, spleen, and lymph nodes of the SCID mice, in a pattern resembling human acute lymphocytic leukemia."
Comparable animal models for the growth of normal 
MATERIALS AND METHODS
Patient samples and cell lines. BM samples were obtained with appropriate informed consent from patients at UCLA with AML, chronic-phase CML, and blast crisis CML. All 12 patients had active leukemia at the time of marrow sampling and implantation into SCID mice. Marrow samples were processed by centrifugation over Ficoll-Hypaque, and all cells present in the low density fraction up to the red blood cell pellet were collected so that some stromal elements were retained. Cells were washed twice in Lymphoblasts in spleen, lymph nodes, EM, blood (Ph' ALL) *Latency is the time after inoculation before animals became ill from growth of leukemia cells.
phosphate-buffered saline (PBS), and then resuspended at 5 to 10 x 10' cellslml in Hanks Balanced Salt Solution (HBSS) and 0.2% fetal calf serum (FCS) before injection into mice. In an attempt to establish leukemia outgrowths in vitro, a portion of each marrow sample was simultaneously plated in Roswell Park Memorial Institute 1640 media with 20% FCS, and insulin, transferrin, selenenium supplementation at a density of 5 x cells/mL and fed twice weekly. Cell lines included K562'" and EM-2," both derived from CML patients in blast crisis, ALL-I,"' derived from a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), and KG-1," derived from an AML patient.
Immune-deficient SCID (CB-17 scidlscid) mice, originally obtained from Dr Ken DorshMice and human BM implantdon. and 0.2 mL of marrow cells (from a suspension of l@ cellslml) was injected under the renal capsule.
Mice were killed by CO, inhalation in accordance with the UCLA Animal Research regulations at defined intelvals after inoculation of human cells. Cells in the peritoneal cavity were recovered by rinsing with HBSS. The following tissues were harvested on each animal for histologic analysis and DNA extraction: peripheral blood (PB), BM from both femurs and tibias, sternum, spleen, liver, lung, kidneys, and any tumors. Cell suspensions of spleens and tumors were made by compression between glass slides. For histopathologic analysis, tissues were fixed in 10% formalin and paraffin embedded, then 4-km sections were cut and stained with hematoxylin and eosin. Cytocentrifuge slides were
Autopsies.
kind (University of California, Riverside, CA) were bred and maintained in a laminar flow tower in a defined flora colony at UCLA as previously described." Cell lines were inoculated into 20 mice either IV or intraperitoneally (IP) at a dose of 1Vto l0'cells per animal. To compare routes of inoculation marrow samples prepared from PB, BM, and peritoneal washings, air dried, and then stained with Wright's stain.
DNA and protein analysis. For quantitative analysis of human specific DNA sequences in mouse tissues, DNA was prepared directly from tissue samples as described.u DNA concentration from leukemia patients were inoculated into mice by either IV or IP injection, or by surgical implantation into one kidney capsule at a dose of 1 to 5 x 10' cells per animal. Mice receiving IV or IP inoculations were pretreated with 300 rads of radiation, a sublethal dose that may enhance acceptance of xenografts by diminishing any natural killer cell activity." Mice receiving kidney capsule implants were not pretreated with radiation because of the potential negative effects of radiation on the recovery from the surgical procedure. For surgery, mice were anesthetized with inhaled MethoxyRurane, the left kidney was exposed by a flank incision, was quantitated by analysis with Hoechst 33258 dye using a Hoefer TKO 100 fluorometer as described in the manual (Hoefer Scientific Instruments. San Francisco, CA) and equal amounts were loaded into a slot blot apparatus and transferred to Zetaprobe membranes. Membranes were air dried and hybridized overnight with a probe to human Alu sequence, BLUR 8,'' labeled by random priming (Boehringer-Mannheim, Indianapolis, IN). The membranes were washed at high stringency and autoradiographed. A dilution series of human DNA into murine DNA was included in each experiment to quantitate the percentage of human cells in each tissue. Southern analysis for the BCR gene rearrangement was performed as described" using the 0.5-kb EamHI-Pst I genomic fragment spanning BCR exon 3 as a probe!6 Autokinase assay for the BCR-ABL protein was performed as described." 
ground binding of the antibodies to murine cells, these samples were also stained with FITC-conjugated antibody to CD45 and only those PE-positive cells that also stained with FITC were considered human. All samples were simultaneously analyzed using isotype controls. Before addition of antibody, cells were incubated for 1 minute at room temperature in PBS and 0.2% sodium azide with 25% human serum and 25% rat serum to reduce nonspecific binding. Cells were stained for 30 minutes on ice, washed twice with PBS and 0.2% sodium azide, and k e d in 1% paraformaldehyde. Antigen expression was measured using a FACSCAN flow cytometer and Lysis I1 software (Becton Dickinson).
RESULTS
Myeloid leukemia cell lines grow in SCID mice in a pattem resembling human myeloid leukemia. The growth of normal human myeloid cells in vitro is dependent on a stromal cell layer, which provides necessary hematopoietic support- ing elements and growth factors.' The maintenance of certain human hematopoietic cell types on murine stromal cell lines indicates that some of these factors can act across species barriers,' but the murine analogues of certain myeloid growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) are not capable of stimulating human cells. The absence of these human-specific growth factors in the SCID mouse could be a limiting factor for the growth of human myeloid cells. Therefore, to examine the growth of leukemic human myeloid cells in the SCID mouse, we first tested human myeloid leukemias that were adapted to growth in culture without exogenously added human-specific hematopoietic growth factors.
All of the myeloid cell lines we tested grew reproducibly in the hematopoietic tissues of the mice after IV inocula- (Fig IC>, and human myeloblasts were seen in Wright-stained smears of PB and BM (Fig 1A and B) . In some cases, tumors also developed within the peritoneal cavity, usually in the perirenal or mesenteric fat. This finding may be analogous to the occasional myelosarcomas or chloromas found in patients with AML. IP injection of four animals with K562 cells also resulted in growth in all animals, but only as tumors confined to the peritoneal cavity with no detectable growth in hematopoietic tissues. To show that CML cells growing in the mice did not represent a subclone with altered expression or loss of the BCR-ABL gene, mouse tissues were also analyzed for the presence of the BCR-ABL protein P210. Using antisera directed at the C-terminus of ABL followed by an in vitro autokinase assay, P210 was identified in all tumors examined with similar levels of expression (Fig 1D) .
Analogous to the CML lines, two of two mice injected IV with lo7 KG-1 cells, derived from a patient with AML, also grew in the BM and PB within a similar time frame. In focal areas 30% to 50% of the KG-1 cells differentiated to eosinophils (Fig 2) . A possible explanation for this observation would be the action of murine IL-5, which can act on human cells and induce eosinophilic differentiation."
Human myeloid leukemias grow in murine hematopoietic tissues in a pattem distinct from human lymphoid leukemia.
Comparison of the pattern of growth of the human myeloid and lymphoid cell lines showed distinctive distribution within hematopoietic tissues that parallels the usual clinical findings in AMLversus ALL. The three human myeloid cell lines showed growth in the BM and PB at a 10% or greater level, but no more than 0.1% to 1.0% human cells were detected in the spleen, even in moribund animals with a large tumor burden (Fig 3A) . In contrast, a human lymphoid cell line established from a patient with Philadelphia chromosome positive ALL (ALL-1) produced dramatic splenomegaly (Fig 3B) and lymphadenopathy due to leukemic infiltration within 4 to 6 weeks. The human DNA content in both the spleen and BM of these animals was high (10% or greater) (Fig 3A) . Other workers studying the growth of human ALL cells in SCID mice have also reported growth of human lymphoid cells in the ~pleen.'".'~ This differential growth in the spleen of human myeloid and lymphoid leukemias suggests that human myeloid and lymphoid hematopoietic cells retain the ability to differentially recognize specific stromal or extracellular matrix components in murine hematopoietic tissues.
BMfrom patients with AML grows as a leukemia in SCID mice. We extended our analysis to fresh BM samples from four patients with active AML at various stages. To compare growth in vivo to growth in vitro, concurrent attempts were made to establish cell lines from these four patient samples by culturing at a density of 5 x 10' cells/mL in RPMI 1640 media with 20% FCS and insulin, transferrin, selenium supplementation without using specific growth factors or stromal layers. Unlike the cell lines we tested, none of the four fresh human AML samples survived in liquid culture for more than 1 month. Any growth observed in the SCID mouse would indicate that the murine in vivo environment can provide factors required for the growth of these human AML cells that are not present in standard liquid culture conditions. Because of prior work showing the growth of human lymphoid cells in SCID mice,"." for proper interpretation of the results obtained using the clinical samples it was critical to demonstrate that any human cells we detected were myeloid rather than lymphoid. For this reason we used flow cytometry as well as the human Nu slot blot to phenotype the human cells. Tissue samples were first stained with a combination of human and murine antibodies to allow quantitation of human cells, then humanspecific myeloid or lymphoid antibodies to determine phenotype. After transplantation of human AML marrow, mouse tissues were examined at various intervals using human myeloid-specific antibodies CD13 and CD33. For confirmation of their human origin, cells were also stained with the human common leukocyte antigen CD45 and analyzed by two-color fluorescence. DNA slot blots for human-specific Alu sequence were also performed to confirm the flow cytometry findings when the estimate of human cell content was less than 5%.
To determine the best route of inoculation of fresh human leukemia cells, 25 mice were reconstituted by three different methods and the efficiency of engraftment was compared, As shown in Fig 4, implantation of cells either IP or under the kidney capsule permitted a high rate of 2093 recovery of human cells either in murine hematopoietic tissues or in the peritoneal cavity. In contrast to the experiments using established cell lines, IV inoculation of marrow cells failed to give reproducible growth of myeloblasts, except for patient 1, who had a relapsed and chemotherapy-resistant leukemia. Based on these findings, all subsequent analysis was performed on mice reconstituted by IP or renal capsule implantation.
After IP or kidney capsule implantation, myeloblasts from all four AML patients grew locally at the site of inoculation and invaded the surrounding tissues (Table 2) . Analysis at early time points (2 to 4 weeks) showed myeloblasts in the peritoneal cavity and local growth of small tumors. At later time points many animals showed spread of human myeloblasts to murine hematopoietic tissues (see Fig 5) . The percentage of human cells detected in the BM or PB varied from patient to patient and by route of inoculation. In particular, hematopoietic spread occurred more frequently after receiving a kidney capsule implant.
The latency of growth of the human myeloblasts in the mice appeared to roughly correlate with the clinical behavior of the leukemia cells in the patient. Patient 4, whose myeloblasts were not detectable until 36 weeks after inoculation, had newly diagnosed AML and achieved a prompt remission, whereas patients 1 through 3 had relapsed or resistant leukemia. In particular, myeloblasts from patient 1, whose leukemia was resistant to chemotherapy, killed all mice within 13 weeks.
Differential growth of BM from patients in the blast crisis versus chronic phase of CML. Culture of BM cells in vitro from patients with blast crisis CML has led to the development of several cell lines; however, no cell lines have been successfully established from patients in the chronic phase of CML. In fact, when marrow cells from chronic-phase patients are cultured in vitro, the normal hematopoietic cells gain a selective growth advantage over the Philadelphiapositive cells.29 To compare the growth characteristics of chronic phase versus blast crisis cells in an in vivo setting, we reconstituted 25 SCID mice with marrow samples from two patients with myeloid blast crisis and six patients with chronic-phase CML (Table 3) by the IP or renal capsule implant routes.
The majority of cells in BM samples from chronic-phase CML patients are terminally differentiated myeloid cells that have a life-span of only hours to days. Upon implantation into SCID mice, we anticipated that most of the myeloid cells from chronic-phase patients would differentiate and die. Therefore, in some cases (patients 7 and 11)
we analyzed mice at multiple time points during the first 4
weeks after inoculation and used antibodies to CD13 and CD33, antigens expressed on myeloid precursor cells, to measure myeloid engraftment. In addition, because of the in vitro behavior with chronic-phase marrow, it was important to evaluate the myeloid versus lymphoid phenotype of human cells within the SCID mouse and to document the presence or absence of the Philadelphia chromosome when possible.
With all six CML patient implants (patients 7 through 12), human cells were recovered from the peritoneal cavity of those mice that received an IP injection within the first 1 to 6 weeks. The number and percentage of human cells declined over time. Serial phenotyping of cells recovered from the peritoneal cavity over the first 3 weeks showed that the percentage of human myeloid progenitor cells (CD13 or CD33 positive) declined over time (Fig 6) . The majority of human cells surviving for greater than 3 weeks were T-lymphoid cells (CD3 positive). Unlike the other chronicphase CML patients, two mice reconstituted with marrow from an Epstein-Barr virus (EBV)-seropositive CML patient (patient 8) showed an increase in human cell recovery and tumor formation in the mesenteric and cervical lymph nodes at 10 to 14 weeks. Phenotype analysis showed these were human B-cell tumors (CD19 positive), and Southern analysis of DNA from the tumors showed germline configuration of the BCR gene (data not shown), indicating that these cells did not arise from the Philadelphia-positive clone. PB cells from EBV-seropositive normal individuals can also give rise to B-cell tumors in SCID mice."-" Only two of the six chronic-phase CML patient samples (patients 10 and 11) resulted in tumor formation. In contrast to the tumors generated from the AML marrows, the chronic-phase CML tumors were focal growths of mature human myeloid cells detected only at 4 to 6 weeks after implantation. In both cases, the growths occurred at the site of injection (see Fig 7A) and did not invade the surrounding tissue. Analysis at a late time point (20 weeks) of marrow injections from patient 10 failed to show any growth. Human cells were not detected in the hematopoietic tissues of any mice after inoculation of any of the six chronic-phase patient marrow samples.
The in vivo behavior of marrow samples from two patients with CML in myeloid blast crisis (patients 5 and 6) was strikingly different. In both cases myeloblasts grew locally and invasively at the site of subcapsular renal implantation (Fig 7B) with a pattern similar to the AML samples. Hematopoietic engraftment was seen for both Fig  7C) . Flow cytometric analysis confirmed that these myeloblasts spread to the BM of the mice and expressed the human marker CD45 and the myeloid markers CD13 and CD33 (Fig 8A and B) . DISCUSSION We show here that cell lines and BM samples from patients with blastic myeloid leukemia can be reproducibly grown in the SCID mouse. Myeloblasts grew as tumors and were detected in the hematopoietic tissues of SCID mice after implantation of marrow samples from four of four AML patients and two of two CML patients in blast crisis. This observation extends the usefulness of the SCID mouse, previously shown to support the growth of human lymphoblastic leukemia, for the study of human myeloid leukemia. An important technical difference in the growth of human lymphoid versus myeloid leukemia samples is that successful transplantation of fresh human myeloid leukemia specimens required transfer of the cells into a localized area, either IP or within the renal capsule. For the human cells to access the murine hematopoietic tissues, the renal capsule approach appears preferable. After initially growing as a myeloid tumor in the kidney capsule, the myeloblasts were detected at varying levels in the circulation and the BM.
The reason for this requirement of a structured implant is not clear. Human stromal components retained in the marrow sample may play a role in the initial establishment of the leukemia as a localized growth. Although samples were processed by centrifugation over a Ficoll-Hypaque density gradient, some stromal elements are retained in the sample and are capable of establishing stromal layers in vitro. Successful growth in the mouse may also require close proximity of the myeloblasts because of autocrine or paracrine production of growth factors. One such molecule that might explain such an interaction would be the c-kit receptor, which is expressed at high frequency in clinical isolates from AML patients, and the kit ligand, which can stimulate the growth of these myeloblast^.^^ Cross reactivity between the murine and human kit ligand might explain the eventual growth of myeloblasts in the hematopoietic organs of the mice.
The different growth patterns of the human myeloid and lymphoid cell lines in the spleen suggest that some homing receptors on the human cells retain the ability to recognize tissue-specific adhesion molecules in the mouse tissues. Although there are species-specific differences in the interaction of leukocyte adhesion molecules with their receptors, certain human leukocyte integrins such as lymphocyte function-associated molecule-1 (LFA-I; CDlla/CD18) will bind to the murine homologue of its counter-receptor Larger numbers of Ah4L patient samples will need to be tested to determine the frequency of successful growth in the SCID mouse. We found that the latency and the degree of invasive growth of the human cells roughly correlated with the clinical behavior of the leukemia. The marrow implant from patient 4, who had newly diagnosed AML and achieved a prompt remission, grew after a 36-week latent period, whereas marrow implants from the other three AML patients, who had suffered multiple relapses, grew within 4 weeks. Interestingly, patient 4 also relapsed after a 36-week remission. Although no firm conclusions should be based on this small number of patients, it may be useful to test the SCID mouse as a predictive model for clinical outcome in AML.
We observed a striking difference in the growth of BM from CML patients in the acute versus the chronic phase of the disease. Acute-phase samples (two of two patients) grew in a fashion analogous to human AML, whereas I C A M -~.~~ chronic-phase samples (six patients) only grew transiently as small, noninvasive nodules or not at all. Serial short-term analysis of human cells recovered from the mice showed preferential survival of the T-or B-lymphoid cells over the myeloblasts present in the chronic-phase marrow samples. Further refinements of the SCID mouse model to more closely approximate the human BM microenvironment may be required to achieve successful transplantation of chronicphase marrow.
The short latency and high frequency of growth of the human myeloid leukemias make the SCID mouse a useful model for testing novel leukemia therapies. Immunotherapy using cytokine-induced cytotoxic killer cells has recently been tested in a human lymphoma model in the SCID mouse." The SCID mouse may also be a useful system to study the molecular events in the progression of CML from the chronic to the acute phase. The biologic effects of mutations introduced into chronic-phase samples by either chemical carcinogens, radiation, or retroviral insertion can be measured.
